DE3546806C2 - - Google Patents

Info

Publication number
DE3546806C2
DE3546806C2 DE3546806A DE3546806A DE3546806C2 DE 3546806 C2 DE3546806 C2 DE 3546806C2 DE 3546806 A DE3546806 A DE 3546806A DE 3546806 A DE3546806 A DE 3546806A DE 3546806 C2 DE3546806 C2 DE 3546806C2
Authority
DE
Germany
Prior art keywords
dna
host cells
genes
stochastic
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3546806A
Other languages
German (de)
English (en)
Inventor
Marc Genf/Geneve Ch Ballivet
Stuart Alan Bryn Mawr Pa. Us Kauffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kauffmann Stuart Alan Santa Fe Nmex Us
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3546806(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE3546806C2 publication Critical patent/DE3546806C2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE3546806A 1985-03-30 1985-06-17 Expired - Lifetime DE3546806C2 (en, 2012)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH137985 1985-03-30

Publications (1)

Publication Number Publication Date
DE3546806C2 true DE3546806C2 (en, 2012) 1991-03-28

Family

ID=4209046

Family Applications (7)

Application Number Title Priority Date Filing Date
DE198585902946T Pending DE229046T1 (de) 1985-03-30 1985-06-17 Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
DE19853590766 Pending DE3590766T (en, 2012) 1985-03-30 1985-06-17
DE3546807A Expired - Lifetime DE3546807C2 (en, 2012) 1985-03-30 1985-06-17
DE3588239T Expired - Lifetime DE3588239T3 (de) 1985-03-30 1985-06-17 Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren
DE3546806A Expired - Lifetime DE3546806C2 (en, 2012) 1985-03-30 1985-06-17
DE3587814T Expired - Lifetime DE3587814T2 (de) 1985-03-30 1985-06-17 Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
DE3590766A Expired - Lifetime DE3590766C2 (en, 2012) 1985-03-30 1985-06-17

Family Applications Before (4)

Application Number Title Priority Date Filing Date
DE198585902946T Pending DE229046T1 (de) 1985-03-30 1985-06-17 Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
DE19853590766 Pending DE3590766T (en, 2012) 1985-03-30 1985-06-17
DE3546807A Expired - Lifetime DE3546807C2 (en, 2012) 1985-03-30 1985-06-17
DE3588239T Expired - Lifetime DE3588239T3 (de) 1985-03-30 1985-06-17 Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE3587814T Expired - Lifetime DE3587814T2 (de) 1985-03-30 1985-06-17 Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
DE3590766A Expired - Lifetime DE3590766C2 (en, 2012) 1985-03-30 1985-06-17

Country Status (14)

Country Link
US (7) US5723323A (en, 2012)
EP (3) EP0590689B2 (en, 2012)
JP (4) JP2584613B2 (en, 2012)
CN (1) CN86102090A (en, 2012)
AU (1) AU4434585A (en, 2012)
CA (2) CA1341595C (en, 2012)
CH (1) CH0229046H1 (en, 2012)
DE (7) DE229046T1 (en, 2012)
FR (1) FR2579618B1 (en, 2012)
GB (1) GB2183661B (en, 2012)
HK (1) HK20292A (en, 2012)
IN (2) IN165561B (en, 2012)
SG (1) SG7992G (en, 2012)
WO (1) WO1986005803A1 (en, 2012)

Families Citing this family (765)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866363A (en) * 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US20060008806A1 (en) * 1986-07-17 2006-01-12 University Of Washington Method for producing novel DNA sequence with biological activity
US5824469A (en) * 1986-07-17 1998-10-20 University Of Washington Method for producing novel DNA sequences with biological activity
US5266684A (en) * 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
WO1991005058A1 (en) * 1989-10-05 1991-04-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
ATE212059T1 (de) * 1990-02-15 2002-02-15 Methoden zur identifizierung heterofunktionaler fusionsproteine
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
US5837834A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6716580B2 (en) 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5726017A (en) * 1990-06-11 1998-03-10 Nexstar Pharmaceuticals, Inc. High affinity HIV-1 gag nucleic acid ligands
US5763177A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5846713A (en) * 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US6140490A (en) * 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US6465189B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5543293A (en) * 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5853984A (en) * 1990-06-11 1998-12-29 Nexstar Pharmaceuticals, Inc. Use of nucleic acid ligands in flow cytometry
US5707796A (en) * 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US6030776A (en) * 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
US5686592A (en) * 1990-06-11 1997-11-11 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5637459A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5789163A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Enzyme linked oligonucleotide assays (ELONAS)
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6127119A (en) * 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5962219A (en) 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US5837456A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5731424A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5874557A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US5750342A (en) * 1990-06-11 1998-05-12 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5756287A (en) * 1990-06-11 1998-05-26 Nexstar Pharmaceuticals, Inc. High affinity HIV integrase inhibitors
US20040132067A1 (en) * 1990-06-11 2004-07-08 Somalogic, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5780228A (en) * 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5637682A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to the tachykinin substance P
US6331394B1 (en) 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US5688935A (en) * 1990-06-11 1997-11-18 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5641629A (en) * 1990-06-11 1997-06-24 Nexstar Pharmacueticals Inc Spectroscopically detectable nucleic acid ligands
US6696252B2 (en) 1990-06-11 2004-02-24 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5587468A (en) * 1990-06-11 1996-12-24 University Research Corporation High affinity nucleic acid ligands to HIV integrase
US5869641A (en) * 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US6001577A (en) * 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5861254A (en) * 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5693502A (en) * 1990-06-11 1997-12-02 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US6177557B1 (en) 1990-06-11 2001-01-23 Nexstar Pharmaceuticals, Inc. High affinity ligands of basic fibroblast growth factor and thrombin
US5629155A (en) * 1990-06-11 1997-05-13 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5567588A (en) * 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5789157A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6124449A (en) * 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US6759392B1 (en) 1990-06-11 2004-07-06 Gilead Sciences, Inc. High affinity RNA ligands of basic fibroblast growth factor
US5795721A (en) * 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US5972599A (en) * 1990-06-11 1999-10-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US5763566A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5766853A (en) * 1990-06-11 1998-06-16 Nexstar Pharmaceuticals, Inc. Method for identification of high affinity nucleic acid ligands to selectins
RU2198931C2 (ru) * 1990-06-11 2003-02-20 Нексстар Фармасьютикалс Инк. Способ идентификации лигандов, способ получения антитела, способ отбора нуклеиновой кислоты, способ получения смеси нуклеиновых кислот, смесь нуклеиновых кислот, не встречающийся в природе нуклеиново-кислотный лиганд
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US20060084797A1 (en) * 1990-06-11 2006-04-20 Gilead Sciences, Inc. High affinity TGFbeta nucleic acid ligands and inhibitors
US5849890A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US5527894A (en) * 1990-06-11 1996-06-18 Nexstar Pharmacueticals, Inc. Ligands of HIV-1 tat protein
US5874218A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US6569620B1 (en) 1990-06-11 2003-05-27 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5731144A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5712375A (en) * 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5864026A (en) * 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6001988A (en) * 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5580737A (en) * 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
US6762290B1 (en) 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US6028186A (en) * 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
WO1993003172A1 (en) * 1991-08-01 1993-02-18 University Research Corporation Systematic polypeptide evolution by reverse translation
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5656467A (en) * 1992-01-09 1997-08-12 The Trustees Of The University Of Pennsylvania Methods and materials for producing gene libraries
ES2231769T3 (es) * 1992-03-16 2005-05-16 Jacob N. Wohlstadter Procedimientos de mutagenesis y seleccion en las mismas celulas huesped.
US5869644A (en) * 1992-04-15 1999-02-09 The Johns Hopkins University Synthesis of diverse and useful collections of oligonucleotidies
US5719273A (en) * 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US5998142A (en) * 1993-09-08 1999-12-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
CA2173990A1 (en) * 1993-10-12 1995-04-20 Narasinga Rao A library of glyco-peptides useful for identification of cell adhesion inhibitors
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
ATE300610T1 (de) 1994-01-31 2005-08-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US20060257890A1 (en) * 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6165793A (en) * 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US7153948B2 (en) 1994-04-25 2006-12-26 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US6048698A (en) * 1994-09-20 2000-04-11 Nexstar Pharmaceuticals, Inc. Parallel SELEX™
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
CA2200684A1 (en) * 1994-09-21 1996-03-28 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
WO1996034875A1 (en) * 1995-05-03 1996-11-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
JP4531132B2 (ja) 1995-06-02 2010-08-25 ギリード・サイエンシズ・インコーポレーテッド 増殖因子に対する高親和性オリゴヌクレオチドリガンド
US6183967B1 (en) 1995-06-07 2001-02-06 Nexstar Pharmaceuticals Nucleic acid ligand inhibitors to DNA polymerases
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6475806B1 (en) 1995-06-07 2002-11-05 Praecis Pharmaceuticals, Inc. Anchor libraries and identification of peptide binding sequences
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US20090118481A1 (en) * 1995-06-07 2009-05-07 Gilead Sciences, Inc. High Affinity Nucleic Acid Ligands To Lectins
AU726844B2 (en) * 1995-06-07 2000-11-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands that bind to and inhibit DNA polymerases
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6361974B1 (en) * 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US20020164580A1 (en) * 1995-12-07 2002-11-07 Diversa Corporation Combinatorial screening of mixed populations of organisms
US20020028443A1 (en) * 1999-09-27 2002-03-07 Jay M. Short Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process
CA2244222A1 (en) 1996-01-23 1997-07-31 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and rna molecules
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6838238B1 (en) 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
US6426335B1 (en) * 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6355426B2 (en) 1996-10-31 2002-03-12 Smithkline Beecham Corporation Methods for the characterization and selection of RNA target motifs that bind compounds of pharmaceutical use
US20070009930A1 (en) * 1996-12-18 2007-01-11 Maxygen, Inc. Methods and compositions for polypeptide engineering
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
DK1717322T3 (da) 1997-01-17 2012-10-22 Codexis Mayflower Holdings Llc Udvikling af hele celler og organismer ved rekursiv sekvensrekombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
EP0971946B1 (en) 1997-01-21 2006-07-05 The General Hospital Corporation Selection of proteins using rna-protein fusions
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US8207093B2 (en) * 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US5871924A (en) * 1997-01-27 1999-02-16 Nexstar Pharmaceuticals, Inc. Method for the production of ligands capable of facilitating aminoacyl-RNA synthesis
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6180341B1 (en) 1997-05-01 2001-01-30 Board Of Regents, The Universiry Of Texas System In vitro scanning saturation mutagenesis of proteins
US6391547B1 (en) * 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
EP1690868A1 (en) 1997-10-31 2006-08-16 Maxygen, Inc. Modification of virus tropism and host range by viral genome shuffling
EP1036198B1 (en) 1997-12-08 2012-09-26 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
US20030219803A1 (en) * 1997-12-15 2003-11-27 Somalogic, Incorporated Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US5989823A (en) * 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6261783B1 (en) 1997-12-15 2001-07-17 Gilead Sciences, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
FR2782325B1 (fr) * 1998-08-12 2002-05-24 Proteus Procede d'identification de sequences polynucleotidiques et/ou des proteines correspondantes a partir d'un echantillon d'acides nucleiques
US7157083B2 (en) * 1998-04-17 2007-01-02 Surrogate Pharmaceutical Pathways, Llc Compositions and methods for treating retroviral infections
NZ507591A (en) 1998-05-01 2002-03-28 Maxygen Inc Optimization of pest resistance genes using DNA shuffling
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
EP1100890A2 (en) 1998-07-27 2001-05-23 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
AU757955B2 (en) 1998-08-17 2003-03-13 Bristol-Myers Squibb Company Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules
US6773911B1 (en) * 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
US6570003B1 (en) * 2001-01-09 2003-05-27 Lexion Genetics Incorporated Human 7TM proteins and polynucleotides encoding the same
US20020128462A1 (en) * 2000-10-30 2002-09-12 Yi Hu Novel human 7TM proteins and polynucleotides encoding the same
AU774306B2 (en) * 1999-01-05 2004-06-24 Trustees Of Boston University Improved nucleic acid cloning
EP1151409A1 (en) * 1999-01-18 2001-11-07 Maxygen, Inc. Methods of populating data stuctures for use in evolutionary simulations
US20030054390A1 (en) * 1999-01-19 2003-03-20 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US20070065838A1 (en) * 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US20090130718A1 (en) * 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
CA2362737A1 (en) 1999-03-05 2000-09-08 Maxygen, Inc. Recombination of insertion modified nucleic acids
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7332308B1 (en) 1999-05-21 2008-02-19 The Penn State Research Foundation Incrementally truncated nucleic acids and methods of making same
US6280943B1 (en) 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
JP4737903B2 (ja) 1999-07-07 2011-08-03 ザイモジェネティクス， インコーポレイテッド ヒトサイトカイン受容体
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
DE60042021D1 (de) * 1999-07-29 2009-05-28 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
US6171795B1 (en) 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
US7005260B1 (en) 2000-01-28 2006-02-28 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6797510B1 (en) * 2001-05-24 2004-09-28 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6759527B2 (en) 2001-03-20 2004-07-06 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6541252B1 (en) 2000-05-19 2003-04-01 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6586230B1 (en) 2000-10-27 2003-07-01 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6841377B1 (en) * 2001-06-13 2005-01-11 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US20080050809A1 (en) * 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
US6734009B2 (en) 2000-12-27 2004-05-11 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20030180714A1 (en) * 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
US7022479B2 (en) * 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
ATE322558T1 (de) 2000-01-24 2006-04-15 Compound Therapeutics Inc Sensible und multiplexe diagnostische tests zur proteinanalyse
EP1250435B1 (en) * 2000-01-26 2006-04-12 Lexicon Genetics Incorporated Human neurexin-like proteins and polynucleotides encoding the same
US20050239061A1 (en) * 2000-03-01 2005-10-27 Marshall William S Identification and use of effectors and allosteric molecules for the alteration of gene expression
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
AU2001289284A1 (en) * 2000-04-04 2001-10-15 Enanta Pharmaceuticals, Inc. Methods for identifying peptide aptamers capable of altering a cell phenotype
US20040029113A1 (en) * 2000-04-17 2004-02-12 Ladner Robert C. Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
AU2001257091A1 (en) * 2000-04-18 2001-10-30 Gilead Sciences, Inc. Aptamer based two-site binding assay
US6479262B1 (en) 2000-05-16 2002-11-12 Hercules, Incorporated Solid phase enzymatic assembly of polynucleotides
AU2001274923A1 (en) * 2000-05-23 2001-12-03 Lexicon Genetics Incorporated Novel human thrombospondin-like proteins and polynucleotides encoding the same
WO2001094583A2 (en) * 2000-06-07 2001-12-13 Lexicon Genetics Incorporated Human transporter proteins and polynucleotides encoding the same
US6465632B1 (en) 2000-06-09 2002-10-15 Lexicon Genetics Incorporated Human phosphatases and polynucleotides encoding the same
AU2001266844A1 (en) * 2000-06-09 2001-12-17 Lexicon Genetics Incorporated Novel human seven transmembrane proteins and polynucleotides encoding the same
AU2001270266B2 (en) 2000-06-28 2004-10-21 Amgen Inc. Thymic stromal lymphopoietin receptor molecules and uses thereof
US6994963B1 (en) 2000-07-10 2006-02-07 Ambion, Inc. Methods for recombinatorial nucleic acid synthesis
WO2002006456A1 (en) * 2000-07-13 2002-01-24 Invitrogen Corporation Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
AU2001277014A1 (en) * 2000-07-21 2002-02-05 Trustees Of Boston University Modular vector systems
US7087415B2 (en) * 2000-07-31 2006-08-08 Athena Biotechnologies, Inc. Methods and compositions for directed gene assembly
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
AU2001283094A1 (en) * 2000-08-07 2002-02-18 Sloan-Kettering Institute For Cancer Research Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
AU2001286792A1 (en) * 2000-08-22 2002-03-04 Lexicon Genetics Incorporated Novel human 7TM proteins and polynucleotides encoding the same
AU2001285326A1 (en) * 2000-08-31 2002-03-13 Lexicon Genetics Incorporated Human kinase proteins and polynucleotides encoding the same
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
AU9630501A (en) 2000-09-26 2002-04-08 Univ Duke Rna aptamers and methods for identifying the same
US20020155460A1 (en) * 2000-10-10 2002-10-24 Genencor International Inc. Information rich libraries
CA2425605A1 (en) 2000-10-16 2002-04-25 Gilead Sciences, Inc. Nucleic acid ligands to the prostate specific membrane antigen
JP2004533221A (ja) * 2000-10-27 2004-11-04 レキシコン・ジェネティクス・インコーポレーテッド 新規ヒト７ｔｍタンパクおよびそれをコードするポリヌクレオチド
AU2002228633A1 (en) * 2000-11-20 2002-06-03 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
AU2002220275A1 (en) * 2000-12-08 2002-06-18 The Board Of Trustees Of The University Of Illinois Mutated class ii major histocompatibility proteins
WO2002055685A2 (en) 2000-12-11 2002-07-18 Lexicon Genetics Incorporated Novel human kinase and polynucleotides encoding the same
JP2004530417A (ja) * 2000-12-12 2004-10-07 レキシコン・ジェネティクス・インコーポレーテッド 新規ヒトキナーゼおよびそれをコードするポリヌクレオチド
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
CA2432377C (en) 2000-12-18 2012-10-09 Dyax Corp. Focused libraries of genetic packages
US6852844B1 (en) * 2000-12-20 2005-02-08 Lexicon Genetics Incorporated Human protocadherin proteins and polynucleotides encoding the same
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
JP4061043B2 (ja) 2000-12-28 2008-03-12 株式会社ポストゲノム研究所 ｉｎｖｉｔｒｏ転写／翻訳系によるペプチド等の製造方法
WO2002059287A2 (en) * 2001-01-23 2002-08-01 Lexicon Genetics Incorporated Novel human kinases and polynucleotides encoding the same
US7838219B2 (en) * 2001-02-02 2010-11-23 Novici Biotech Llc Method of increasing complementarity in a heteroduplex
US20040142433A1 (en) * 2001-02-02 2004-07-22 Padgett Hal S. Polynucleotide sequence variants
US7582423B2 (en) * 2001-02-02 2009-09-01 Novici Biotech Llc Population of polynucleotide sequence variants
DE60234159D1 (de) 2001-02-02 2009-12-10 Large Scale Biology Corp Methode zur erhöhung der komplementarität in einem heteroduplex-polynucleotid
WO2002065125A1 (en) * 2001-02-13 2002-08-22 Invitrogen Corporation Methods and compositions for isolation of biological macromolecules
WO2002068630A1 (en) * 2001-02-22 2002-09-06 Praecis Pharmaceuticals Incorporated Methods for identifying peptides which modulate a biological process
EP1370676A4 (en) 2001-03-02 2004-09-22 Zymogenetics Inc CYTOKIN RECEPTOR FROM MOUSE
US7807408B2 (en) * 2001-03-19 2010-10-05 President & Fellows Of Harvard College Directed evolution of proteins
AU2002257076A1 (en) 2001-03-19 2002-10-03 President And Fellows Of Harvard College Nucleic acid shuffling
EP1383880A1 (en) * 2001-04-06 2004-01-28 Lexicon Genetics Incorporated Novel human kinase and polynucleotides encoding the same
CA2443516A1 (en) * 2001-04-06 2002-10-17 Lexicon Genetics Incorporated Novel human kinases and polynucleotides encoding the same
US6644173B2 (en) * 2001-04-11 2003-11-11 Keuring, Incorporated Beverage filter cartridge holder
AU2002254773B2 (en) * 2001-05-03 2005-12-08 Rensselaer Polytechnic Institute Novel methods of directed evolution
CA2446967A1 (en) * 2001-05-09 2002-11-14 Lexicon Genetics Incorporated Novel human kinases and polynucleotides encoding the same
PT2070939E (pt) 2001-05-25 2014-06-09 Univ Duke Moduladores de agentes farmacológicos
WO2002097095A1 (en) * 2001-05-25 2002-12-05 Lexicon Genetics Incorporated Novel human transporter proteins and polynucleotides encoding the same
CA2448347C (en) 2001-05-29 2010-09-21 Lexicon Genetics Incorporated Novel human hydroxylases and polynucleotides encoding the same
US20030148380A1 (en) * 2001-06-05 2003-08-07 Belcher Angela M. Molecular recognition of materials
US20030113714A1 (en) * 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20050164515A9 (en) * 2001-06-05 2005-07-28 Belcher Angela M. Biological control of nanoparticle nucleation, shape and crystal phase
WO2003000113A2 (en) 2001-06-20 2003-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DE10131441A1 (de) * 2001-06-29 2003-01-30 Henkel Kgaa Eine neue Gruppe von alpha-Amylasen sowie ein Verfahren zur Identifizierung und Gewinnung neuer alpha-Amylasen
US20040204669A1 (en) * 2001-07-05 2004-10-14 Hofmann Gunter A. Apparatus for electroporation mediated delivery for drugs and genes
US20030148264A1 (en) * 2001-07-06 2003-08-07 Genentech, Inc. Phage displayed PDZ domain ligands
CA2456229A1 (en) * 2001-08-03 2003-02-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
US6943001B2 (en) * 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
DE10138753B4 (de) * 2001-08-07 2017-07-20 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit Hybrid-Alpha-Amylasen
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
MXPA04002593A (es) 2001-09-18 2004-05-31 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumor.
ES2405551T3 (es) 2001-10-01 2013-05-31 Dyax Corporation Vectores de presentación eucariotas multicatenarios y usos de los mismos
US20030073104A1 (en) * 2001-10-02 2003-04-17 Belcher Angela M. Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus
EP1840211A1 (en) 2001-10-31 2007-10-03 Danisco A/S Pyranosone dehydratase from phanerochaete chrysosporium
EP2308888B1 (en) 2001-11-14 2017-03-01 Janssen Biotech, Inc. Anti-IL-6 antibodies, compositions, methods and uses
WO2003072542A2 (en) * 2001-11-20 2003-09-04 Duke University Interfacial biomaterials
AU2002366523A1 (en) * 2001-12-05 2003-06-23 E-Tenna Corporation Capacitively-loaded bent-wire monopole on an artificial magnetic conductor
US7179907B2 (en) 2001-12-18 2007-02-20 Bruce Eaton Antibiotic compounds
WO2003057921A1 (en) * 2001-12-26 2003-07-17 Sloan Kettering Institute For Cancer Research Dna immunization with libraries of minigenes encoding degenerate variants of major histocompatibility class i restricted epitopes
NZ556415A (en) 2002-01-02 2009-02-28 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
WO2003064612A2 (en) * 2002-01-28 2003-08-07 Sloan-Kettering Institute For Cancer Research Identification of mutant antigens with enhanced immunogenicity
US20030157495A1 (en) * 2002-02-01 2003-08-21 Padgett Hal S. Nucleic acid molecules encoding CEL I endonuclease and methods of use thereof
US7078211B2 (en) * 2002-02-01 2006-07-18 Large Scale Biology Corporation Nucleic acid molecules encoding endonucleases and methods of use thereof
AU2003217379A1 (en) 2002-02-15 2003-09-09 Somalogic, Inc. Methods and reagents for detecting target binding by nucleic acid ligands
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US20040025194A1 (en) * 2002-02-22 2004-02-05 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
WO2003072054A2 (en) * 2002-02-25 2003-09-04 Cabot Corporation Custom ligand design for biomolecular filtration and purification for bioseperation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
CA2481411C (en) 2002-04-19 2016-06-14 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
WO2003102157A2 (en) * 2002-06-03 2003-12-11 Genentech, Inc. Synthetic antibody phage libraries
DE60319259T2 (de) * 2002-06-14 2009-03-05 Dyax Corp., Cambridge Rekombination von nukleinsäurebibliotheksmitgliedern
WO2003106659A2 (en) * 2002-06-18 2003-12-24 Archemix Corp. Aptamer-toxin molecules and methods for using same
JP2005533862A (ja) * 2002-07-25 2005-11-10 アーケミックス コーポレイション 調節されたアプタマー治療剤
EP1576151A4 (en) 2002-08-06 2006-05-17 Verdia Inc AP1-amine oxidase VARIATIONS
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
EP1539960B1 (en) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
US20050064508A1 (en) * 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
AU2003279719B8 (en) 2002-09-27 2009-01-08 Xencor Inc. Optimized Fc variants and methods for their generation
JP3447009B1 (ja) * 2002-10-29 2003-09-16 實 平垣 構築物用構成体およびその製造方法
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
AU2003294437A1 (en) * 2002-11-21 2004-06-18 Archemix Corporation Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
EP1570085A4 (en) * 2002-12-03 2007-07-25 Archemix Corp PROCESS FOR IN VITRO SELECTION OF 2'-SUBSTITUTED NUCLEIC ACIDS
CA2509568A1 (en) * 2002-12-26 2004-07-15 Applied Research Systems Ars Holding N.V. Spliced variants of lgr6
AU2004205631A1 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CN102618564B (zh) 2003-03-06 2014-10-29 维莱尼姆公司 淀粉酶、编码它们的核酸及其制备和应用方法
US8298799B2 (en) 2003-03-07 2012-10-30 Dsm Ip Assets B. V. Hydrolases, nucleic acids encoding them and methods for making and using them
HUE030493T2 (en) 2003-04-04 2017-05-29 Basf Enzymes Llc Pectate lyases, nucleic acids and processes encoding them for their production and use
US20050250106A1 (en) * 2003-04-24 2005-11-10 David Epstein Gene knock-down by intracellular expression of aptamers
AU2003241409A1 (en) * 2003-05-12 2005-01-21 Potomac Pharmaceuticals, Inc. Gene expression suppression agents
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP2404928A1 (en) 2003-07-02 2012-01-11 Verenium Corporation Glucanases, nucleic acids encoding them and methods for making and using them
AU2004259638C1 (en) 2003-07-08 2018-12-20 Novartis Pharma Ag IL-17 A/F heterologous polypeptides and therapeutic uses thereof
WO2005012487A2 (en) * 2003-08-01 2005-02-10 Invitrogen Corporation Compositions and methods for preparing short rna molecules and other nucleic acids
JP2007501011A (ja) * 2003-08-01 2007-01-25 ジェネンテック・インコーポレーテッド 制限多様性配列を有する結合型ポリペプチド
US7741089B2 (en) 2003-08-11 2010-06-22 Verenium Corporation Laccases, nucleic acids encoding them and methods for making and using them
JP2005065575A (ja) * 2003-08-22 2005-03-17 Japan Science & Technology Agency フレームシャッフリングによるタンパク質分子多様性集団の作製
JP2007528723A (ja) * 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
JP4901478B2 (ja) 2003-11-17 2012-03-21 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
US20050112585A1 (en) * 2003-11-21 2005-05-26 Dominic Zichi Method for adjusting the quantification range of individual analytes in a multiplexed assay
AU2004297616B2 (en) * 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
EP1701672A4 (en) * 2003-12-19 2011-04-27 Osteotech Inc TISSUE-BASED MESH FOR BONE REGENERATION
JP5242918B2 (ja) 2004-02-12 2013-07-24 アーケミックス エルエルシー 補体関連障害の治療に有用なアプタマー治療法
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
BRPI0508363A (pt) * 2004-03-05 2007-07-24 Archemix Corp aptámeros para a famìlia de citocinas de il-12 humana e seus usos como terapia de doença auto-imune
US7569223B2 (en) * 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20080214489A1 (en) * 2004-04-19 2008-09-04 Anthony Dominic Keefe Aptamer-mediated intracellular delivery of oligonucleotides
DK1745062T3 (da) * 2004-04-22 2014-08-11 Regado Biosciences Inc Forbedrede modulatorer af koagulationsfaktorer
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
WO2005106012A2 (en) 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
EP1789453A2 (en) * 2004-05-18 2007-05-30 Genentech, Inc. M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
JP2008505619A (ja) 2004-06-16 2008-02-28 ヴェレニウム コーポレイション 葉緑素を酵素的に脱色するための組成物及び方法
KR20070101227A (ko) 2004-09-07 2007-10-16 아케믹스 코포레이션 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
KR20070101226A (ko) * 2004-09-07 2007-10-16 아케믹스 코포레이션 앱타머의 약화학
GB0422052D0 (en) 2004-10-04 2004-11-03 Dansico As Enzymes
GB0423139D0 (en) * 2004-10-18 2004-11-17 Danisco Enzymes
EP2332985A3 (en) 2004-11-12 2012-01-25 Xencor, Inc. Fc variants with altered binding to FcRn
RS50830B (sr) 2005-01-05 2010-08-31 F-Star Biotechnologische Forschungs-Und Entwicklungsges M.B.H. Sintetički domeni imunoglobulina sa vezujućim svojstvima izgrađenim u područjima molekula različitim od komplementarno određujućih područja
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
CA2596390A1 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
ZA200707490B (en) 2005-03-10 2008-12-31 Genentech Inc Methods and compositions for modulatiing vascular integrity
CA2614769A1 (en) 2005-03-10 2006-09-21 Verenium Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
NZ594810A (en) 2005-03-15 2012-12-21 Verenium Corp Cellulases, nucleic acids encoding them and methods for making and using them
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
JP2008544746A (ja) 2005-05-12 2008-12-11 ザイモジェネティクス， インコーポレイテッド 免疫応答を調節するための組成物および方法
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
US8389469B2 (en) * 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
KR20130080058A (ko) * 2005-06-30 2013-07-11 아보트 러보러터리즈 Ｉｌ-12/ｐ40 결합 단백질
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500352A1 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
EP2500354A3 (en) 2005-08-19 2012-10-24 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101297034A (zh) 2005-08-24 2008-10-29 洛克菲勒大学 Ply-gbs突变溶素
WO2007035527A2 (en) 2005-09-15 2007-03-29 Duke University Non-fouling polymeric surface modification and signal amplification method for biomolecular detection
US8906864B2 (en) * 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
MX2008008621A (es) 2005-12-29 2008-11-27 Centocor Inc Anticuerpos anti-il-23 humanos, composiciones, metodos y usos.
US20090324574A1 (en) 2006-02-02 2009-12-31 Verenium Corporation Esterases and Related Nucleic Acids and Methods
WO2007092313A2 (en) * 2006-02-03 2007-08-16 Indiana University Research And Technology Corporation Construction of open reading frame libraries and protein structures
DK2444487T3 (en) 2006-02-10 2018-05-28 Bp Corp North America Inc CELLULOLYTIC ENZYMES, NUCLEIC ACIDS, CODING THEM, AND PROCEDURES FOR THEIR PREPARATION AND USE
EP2548956A1 (en) 2006-02-14 2013-01-23 Verenium Corporation Xylanases, nucleic acids encoding them and methods for making and using them
JP5441417B2 (ja) 2006-03-07 2014-03-12 カーギル・インコーポレイテッド アルドース、それをコードする核酸、ならびにそれを生成および使用する方法
CN102690833B (zh) 2006-03-07 2015-09-09 巴斯夫酶有限责任公司 醛缩酶、编码它们的核酸及制备和使用它们的方法
KR101513308B1 (ko) * 2006-03-08 2015-04-28 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
JP2009536527A (ja) * 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
AT503902B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
CN101511868B (zh) 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
CN106222185B (zh) 2006-08-04 2021-12-03 维莱尼姆公司 葡聚糖酶、编码它们的核酸及制备和使用它们的方法
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
ES2817756T3 (es) 2006-09-08 2021-04-08 Abbvie Bahamas Ltd Proteínas de unión a interleuquina-13
EP2083017A4 (en) 2006-09-14 2011-01-12 Med & Biological Lab Co Ltd ANTIBODIES HAVING INCREASED ADCC ACTIVITY AND METHOD FOR PRODUCING THE SAME
EP2617822A3 (en) 2006-09-21 2013-10-16 Verenium Corporation Phytases, nucleic acids encoding them and methods for making and using them
AR062947A1 (es) 2006-09-21 2008-12-17 Verenium Corp Fosfolipasas acidos nucleicos que las codifican y metodos para prepararlas y usarlas
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PL2479267T3 (pl) 2006-12-21 2017-06-30 Basf Enzymes Llc Amylazy i glukoamylazy, kwasy nukleinowe kodujące te związki oraz sposoby wytwarzania tych związków oraz stosowania ich
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
EP2126117A2 (en) * 2007-01-18 2009-12-02 University Of Southern California Gene polymorphisms predictive for dual tki therapy
CN101652381B (zh) 2007-01-30 2014-04-09 维莱尼姆公司 用于处理木质纤维素的酶、编码它们的核酸及其制备和应用方法
US8143046B2 (en) 2007-02-07 2012-03-27 Danisco Us Inc., Genencor Division Variant Buttiauxella sp. phytases having altered properties
BRPI0807952A2 (pt) * 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
WO2008103962A2 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
EP2124952A2 (en) * 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US20090175847A1 (en) * 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
CN101802006B (zh) 2007-06-26 2013-08-14 F-星生物技术研究与开发有限公司 展示结合剂
EP2172566B2 (en) 2007-07-17 2022-05-18 Somalogic, Inc. Method for generating aptamers with improved off-rates
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
AU2008298603B2 (en) 2007-09-14 2015-04-30 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
SI2915564T1 (sl) 2007-09-28 2021-03-31 Alexion Pharmaceuticals, Inc. Antidoti za zaviralce dejavnika Ksa in postopki njihove uporabe
USRE46733E1 (en) 2007-10-03 2018-02-27 Bp Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
EP2215108A4 (en) 2007-10-23 2012-07-04 Univ Colorado COMPETITIVE INHIBITORS OF THE EXPRESSION OF THE CONSTANT CHAIN AND / OR THE ECTOPIC CLIP BINDING
WO2009055656A2 (en) 2007-10-26 2009-04-30 Centocor, Inc. Vectors, host cells, and methods of production and uses
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
US20110118447A1 (en) * 2007-12-31 2011-05-19 Xoma Technology Ltd. Methods and materials for targeted affinity enhancement
BRPI0822218A2 (pt) 2008-01-03 2015-06-23 Verenium Corp Transferases e oxidorredutases, ácidos nucleicos que as codificam e métodos para fazê-las e usá-las.
CA2710922A1 (en) 2008-01-03 2009-07-16 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
US7682809B2 (en) 2008-01-11 2010-03-23 Agilent Technologies, Inc. Direct ATP release sequencing
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009114815A1 (en) * 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
WO2009132287A2 (en) 2008-04-24 2009-10-29 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2279248B1 (en) 2008-04-30 2015-04-01 DuPont Nutrition Biosciences ApS Proteins
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
KR101603917B1 (ko) 2008-05-09 2016-03-17 애브비 인코포레이티드 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
TW201006485A (en) * 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2728308A1 (en) 2008-06-20 2009-12-23 Wyeth Llc Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
WO2009154025A1 (ja) 2008-06-20 2009-12-23 国立大学法人岡山大学 酸化LDL/β2GPI複合体に対する抗体及びその用途
AU2009268585C1 (en) * 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
TW201014602A (en) 2008-07-08 2010-04-16 Abbott Lab Prostaglandin E2 binding proteins and uses thereof
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
EP2323680A4 (en) * 2008-07-25 2013-05-01 Viral Genetics Inc PROTEINS FOR USE IN THE DIAGNOSIS AND TREATMENT OF INFECTIONS AND DISEASES
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
CN102177178B (zh) 2008-08-14 2015-07-01 梯瓦制药澳大利亚私人有限公司 抗il-12/il-23抗体
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
CN107011415A (zh) 2008-10-20 2017-08-04 光州科学技术院 双齿肽结合物
KR20110097913A (ko) * 2008-12-04 2011-08-31 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP2379720B1 (en) 2009-01-20 2016-08-17 Alona Zilberberg Mir-21 promoter driven targeted cancer therapy
UA102722C2 (en) * 2009-01-29 2013-08-12 Эббви Инк. Il-1 binding proteins
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
PT3604510T (pt) 2009-03-30 2025-06-24 Alexion Pharma Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
GB0908770D0 (en) 2009-04-24 2009-07-01 Danisco Method
EP2698374B1 (en) 2009-05-21 2016-09-14 BASF Enzymes LLC Phytases, nucleic acids encoding them and methods for making and using them
CA2767858C (en) 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011025964A2 (en) * 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
RU2012112550A (ru) 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
CA2773564A1 (en) * 2009-09-14 2011-03-17 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
EP3187877A1 (en) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening methods
UY32948A (es) 2009-10-15 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UA111708C2 (uk) 2009-10-16 2016-06-10 Бандж Ойлз, Інк. Спосіб рафінування олії
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
CN102711826B (zh) 2009-10-22 2017-03-29 霍夫曼-拉罗奇有限公司 用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053707A1 (en) * 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
PE20121584A1 (es) 2009-11-30 2012-11-29 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores
CN113717286A (zh) * 2009-12-08 2021-11-30 Abbvie德国有限责任两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
JP5981853B2 (ja) 2010-02-18 2016-08-31 ジェネンテック， インコーポレイテッド ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
RU2595389C2 (ru) 2010-02-23 2016-08-27 Дженентек, Инк. Композиции и способы для диагностики и лечения опухолей
TWI781327B (zh) 2010-02-24 2022-10-21 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
SG10201501562VA (en) 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
WO2011109642A1 (en) 2010-03-03 2011-09-09 Somalogic, Inc. Aptamers to 4-1bb and their use in treating diseases and disorders
HUE036157T2 (hu) 2010-03-30 2018-06-28 Janssen Biotech Inc Humanizált IL-25 ellenanyagok
CN104069512A (zh) 2010-04-12 2014-10-01 私募蛋白质体公司 针对β-NGF的适体及其在治疗β-NGF介导的疾病和失调中的用途
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR101539684B1 (ko) 2010-05-14 2015-07-27 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
GB201011513D0 (en) 2010-07-08 2010-08-25 Danisco Method
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3741883B1 (en) 2010-07-16 2022-12-14 Adimab, LLC Antibody libraries
SG188190A1 (en) 2010-08-03 2013-04-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
HRP20220405T1 (hr) 2010-08-19 2022-05-27 Zoetis Belgium S.A. Protutijela protiv ngf i njihova upotreba
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
BR112013008347A2 (pt) 2010-10-06 2016-06-14 Bp Corp North America Inc polipeptídeos de variantes cbh i
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
JP6009455B2 (ja) 2010-12-21 2016-10-19 アッヴィ・インコーポレイテッド Ｉｌ−１アルファおよびベータ二重特異的二重可変ドメイン免疫グロブリンおよびその使用
EP4008781A1 (en) 2010-12-31 2022-06-08 BioAtla, Inc. Express humanization of antibodies
GB2503604B (en) 2011-03-21 2020-04-22 Biodesy Llc Classification of kinase inhibitors using second harmonic optical techniques
CN103857410A (zh) 2011-04-21 2014-06-11 洛克菲勒大学 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
AU2012283039A1 (en) 2011-07-13 2014-01-30 Abbvie Inc. Methods and compositions for treating asthma using anti-IL-13 antibodies
US8609355B2 (en) 2011-07-26 2013-12-17 Indicator Systems International, Inc. Assays for the detection of microbes
MX2014003094A (es) 2011-09-15 2014-04-25 Genentech Inc Metodos para promover diferenciacion.
AU2012318609B2 (en) 2011-10-05 2018-02-08 The Rockefeller University Dimeric bacteriophage lysins
EP2766000A2 (en) 2011-10-15 2014-08-20 F.Hoffmann-La Roche Ag Scd1 antagonists for treating cancer
JP2014533659A (ja) 2011-10-24 2014-12-15 アッヴィ・インコーポレイテッド スクレロスチンに対するイムノバインダー
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
CA2855570A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
WO2013090635A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
CA2862424A1 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
DK2804878T3 (en) 2012-01-20 2018-12-17 Genzyme Corp ANTI-CXCR3 ANTIBODIES
PE20142168A1 (es) 2012-01-27 2015-01-17 AbbVie Deutschland GmbH and Co KG Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
WO2013162654A1 (en) 2012-04-25 2013-10-31 Biodesy, Llc Methods for detecting allosteric modulators of proteins
CN104718220A (zh) 2012-02-11 2015-06-17 霍夫曼-拉罗奇有限公司 R-spondin易位及其使用方法
CA2866612C (en) 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
BR112014020173A8 (pt) 2012-03-16 2017-07-11 Hoffmann La Roche Métodos para o tratamento de um melanoma, utilizações de um inibidor, composições, conjunto, método de inibição, método de identificação, método de ajuste do tratamento e invenção
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
JP6198807B2 (ja) 2012-03-16 2017-09-20 ジェネンテック， インコーポレイテッド 操作され立体構造的に安定化されたタンパク質
WO2013136193A2 (en) 2012-03-16 2013-09-19 University Health Network Methods and compositions for modulating toso activity
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
EP3508497A1 (en) 2012-05-24 2019-07-10 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
PT2890717T (pt) 2012-08-31 2020-04-22 Immunogen Inc Ensaios de diagnóstico e kits para deteção de recetor de folato 1
CN104884472B (zh) 2012-11-01 2021-10-15 艾伯维公司 抗-vegf/dll4双重可变结构域免疫球蛋白及其用途
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
CA2900097A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
HK1213180A1 (zh) 2013-03-06 2016-06-30 豪夫迈‧罗氏有限公司 治疗和预防癌症药物抗性的方法
GB201308828D0 (en) 2013-03-12 2013-07-03 Verenium Corp Phytase
GB201308843D0 (en) 2013-03-14 2013-07-03 Verenium Corp Phytase formulation
EP2971046A4 (en) 2013-03-14 2016-11-02 Abbott Lab MONOCLONAL ANTIBODIES WITH LIPID BINDING TO THE HEART OF HCV
WO2014158272A1 (en) 2013-03-14 2014-10-02 Abbott Laboratories Hcv antigen-antibody combination assay and methods and compositions for use therein
MX2015011606A (es) 2013-03-14 2016-05-17 Genentech Inc Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
MX2015012824A (es) 2013-03-14 2016-06-24 Abbott Lab Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
KR20220053691A (ko) 2013-03-15 2022-04-29 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
EP2971000A4 (en) 2013-03-15 2016-11-23 Pioneer Hi Bred Int PHI-4 POLYPEPTIDES AND METHOD FOR THEIR USE
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
AR095173A1 (es) 2013-07-25 2015-09-30 Basf Enzymes Llc Fitasa
US10006045B2 (en) 2013-08-16 2018-06-26 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
SG11201601037YA (en) 2013-08-30 2016-03-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
EA201600252A1 (ru) 2013-09-12 2017-05-31 Галозим, Инк. Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
MX2018010689A (es) 2013-09-13 2023-01-11 Pioneer Hi Bred Int Proteinas insecticidas y metodos para su uso.
CA2935378C (en) 2013-12-24 2023-04-18 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
PH12016501534B1 (en) 2014-02-07 2024-06-05 Du Pont Insecticidal proteins and methods for their use
US10480007B2 (en) 2014-02-07 2019-11-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants
WO2015132675A2 (en) 2014-03-07 2015-09-11 University Health Network Methods and compositions for modifying the immune response
SG10201913627TA (en) 2014-04-08 2020-03-30 Boston Pharmaceuticals Inc Binding molecules specific for il-21 and uses thereof
MX2016012830A (es) 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
BR112016025751A2 (pt) 2014-05-05 2018-01-16 Regeneron Pharma roedor, e, métodos para fabricar um roedor e um camundongo humanizados e para identificar um composto capaz de modular a ativação de complemento
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
EP3154589A1 (en) 2014-06-13 2017-04-19 Genentech, Inc. Methods of treating and preventing cancer drug resistance
EP3157945A4 (en) 2014-06-20 2017-11-22 F. Hoffmann-La Roche AG Chagasin-based scaffold compositions, methods, and uses
CA2963558C (en) 2014-10-16 2023-04-04 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
EP3209774B1 (en) 2014-10-24 2020-02-26 DuPont Nutrition Biosciences ApS Use of proline tolerant tripeptidyl peptidases in feed additive compositions
WO2016065238A1 (en) 2014-10-24 2016-04-28 Danisco Us Inc. Method for producing alcohol by use of a tripeptidyl peptidase
KR102698502B1 (ko) 2014-11-10 2024-08-26 메디뮨 리미티드 Cd73에 특이적인 결합 분자 및 이의 용도
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
EP3237906B8 (en) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
HK1245134A1 (zh) 2015-01-14 2018-08-24 The Brigham And Women's Hospital, Inc. 用抗lap单克隆抗体治疗癌症
RU2740312C2 (ru) 2015-01-15 2021-01-13 Пайониэ Хай-Бред Интернешнл, Инк. Инсектицидные белки и способы их применения
EA038923B1 (ru) 2015-03-11 2021-11-10 Пайонир Хай-Бред Интернэшнл, Инк. Инсектицидная днк-конструкция и способы её применения
CN116063543A (zh) 2015-04-24 2023-05-05 豪夫迈·罗氏有限公司 多特异性抗原结合蛋白
WO2016186986A1 (en) 2015-05-19 2016-11-24 Pioneer Hi Bred International Inc Insecticidal proteins and methods for their use
EP3626744A1 (en) 2015-05-29 2020-03-25 AbbVie Inc. Anti-cd40 antibodies and uses thereof
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
DK3313882T3 (da) 2015-06-24 2020-05-11 Janssen Pharmaceutica Nv Anti-VISTA antistoffer og fragmenter
EP3314004A1 (en) 2015-06-26 2018-05-02 DuPont Nutrition Biosciences ApS Aminopeptidases for protein hydrolyzates
CN114671951A (zh) 2015-06-29 2022-06-28 伊缪诺金公司 抗cd123抗体以及其缀合物和衍生物
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
HK1255383A1 (zh) 2015-07-31 2019-08-16 The Research Institute At Nationwide Children's Hospital 去除生物膜的肽及抗體
BR112018002535A2 (pt) 2015-08-06 2018-09-25 Du Pont polipeptídeo inseticida recombinante, polinucleotídeo recombinante, construto de dna, planta transgênica ou célula de planta, composição, proteína de fusão, método para controlar uma praga, método para inibir crescimento ou para exterminar uma população de pragas ou uma praga e uso do polipeptídeo
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
WO2017083451A1 (en) 2015-11-10 2017-05-18 Medimmune, Llc Binding molecules specific for asct2 and uses thereof
US20180325119A1 (en) 2015-12-18 2018-11-15 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
JP2019502753A (ja) 2015-12-23 2019-01-31 ムーンショット ファーマ エルエルシー ナンセンス変異依存ｍＲＮＡ分解機構の抑制による免疫応答の誘導法
CN109069626A (zh) 2016-02-12 2018-12-21 詹森药业有限公司 抗-vista(b7h5)抗体
WO2017147060A1 (en) 2016-02-25 2017-08-31 Dupont Nutrition Biosciences Aps Method for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase
PL3426680T3 (pl) 2016-03-10 2025-03-31 Acceleron Pharma Inc. Białka wiążące receptor aktywiny typu 2 i ich zastosowania
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
BR112018069776A2 (pt) 2016-03-29 2019-02-05 Janssen Biotech Inc tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR102405278B1 (ko) 2016-04-22 2022-06-07 악셀레론 파마 인코포레이티드 Alk7 결합 단백질 및 이들의 용도
CN114617962A (zh) 2016-04-27 2022-06-14 艾伯维公司 使用抗-il-13抗体治疗il-13活性在其中有害的疾病的方法
WO2017192560A1 (en) 2016-05-04 2017-11-09 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
RU2745748C2 (ru) 2016-06-02 2021-03-31 Эббви Инк. Агонист глюкокортикоидного рецептора и его иммуноконъюгаты
CA3027044A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
HUE053356T2 (hu) 2016-06-08 2021-06-28 Abbvie Inc B7-H3 elleni antitestek és antitest-hatóanyag konjugátumok
JP2019521973A (ja) 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド 抗ｂｈ７−ｈ３抗体及び抗体薬物コンジュゲート
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
US20190330641A1 (en) 2016-06-17 2019-10-31 National Hellenic Research Foundation Systems for recombinant protein production
EP3954202A1 (en) 2016-07-01 2022-02-16 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
EP3509616A1 (en) 2016-09-09 2019-07-17 H. Hoffnabb-La Roche Ag Selective peptide inhibitors of frizzled
MA46366A (fr) 2016-09-30 2019-08-07 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
MX2019003473A (es) 2016-10-03 2019-10-15 Abbott Lab Metodos mejorados para evaluar el estado de ubiquitin carboxi-terminal hidrolasa l1 (uch-l1) en muestras de pacientes.
EP4050021A1 (en) 2016-11-01 2022-08-31 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
KR20190078648A (ko) 2016-11-16 2019-07-04 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 방법
JP7274417B2 (ja) 2016-11-23 2023-05-16 イミュノア・セラピューティクス・インコーポレイテッド ４－１ｂｂ結合タンパク質及びその使用
KR20190080949A (ko) 2016-11-23 2019-07-08 바이오버라티브 테라퓨틱스 인크. 응고 인자 ｉｘ 및 응고 인자 ｘ에 결합하는 이중특이적 항체
CA3044404A1 (en) 2016-12-14 2018-06-21 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA3046226A1 (en) 2016-12-22 2018-06-28 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
AU2018206560B9 (en) 2017-01-04 2025-04-03 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
CN110709419B (zh) 2017-01-06 2023-11-28 博奥信生物技术（南京）有限公司 Erbb2抗体及其用途
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2018148001A1 (en) 2017-02-08 2018-08-16 Pioneer Hi-Bred International Inc Insecticidal combinations of plant derived insecticidal proteins and methods for their use
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
SG11201907606XA (en) 2017-02-27 2019-09-27 Regeneron Pharma Humanized model of kidney and liver disorders
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CA3052513A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
BR112019021612A2 (pt) 2017-04-15 2020-05-12 Abbott Laboratories Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces
CA3059615A1 (en) 2017-04-21 2018-10-25 Genentech, Inc. Use of klk5 antagonists for treatment of a disease
US11236151B2 (en) 2017-04-25 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
WO2018200823A1 (en) 2017-04-28 2018-11-01 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
MX2019013321A (es) 2017-05-11 2020-02-10 Pioneer Hi Bred Int Proteinas insecticidas y metodos para su uso.
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
BR112019025387A2 (pt) 2017-05-30 2020-07-07 Abbott Laboratories métodos para auxiliar no diagnóstico e avaliação de uma lesão traumática cerebral branda em um indivíduo humano com o uso de troponina cardíaca i e biomarcadores precoces
WO2018237326A1 (en) 2017-06-22 2018-12-27 1AlMOONSHOT PHARMA LLC METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNOMODULATORS
WO2019010131A1 (en) 2017-07-03 2019-01-10 Abbott Laboratories IMPROVED METHODS FOR MEASURING CARBOXY TERMINATION HYDROLASE LEVELS OF UBIQUITIN L1 IN BLOOD
EP3655430A1 (en) 2017-07-19 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
US11680110B2 (en) 2017-07-31 2023-06-20 Hoffmann-La Roche Inc. Three-dimensional structure-based humanization method
MA50098A (fr) 2017-09-05 2020-07-15 Immunogen Inc Procédés de détection du récepteur 1 des folates dans un échantillon provenant d'un patient
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
CN118497126A (zh) 2017-10-04 2024-08-16 赫斯佩瑞克斯股份公司 针对癌症个体化疗法的制品和方法
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
JP2021502125A (ja) 2017-11-09 2021-01-28 ピンテオン セラピューティクス インコーポレイテッド ヒト化コンホメーション特異的リン酸化タウ抗体の作製および使用のための方法および組成物
BR112019028254A2 (pt) 2017-12-09 2020-07-14 Abbott Laboratories métodos para ajudar no diagnóstico e avaliação de um paciente que sofreu uma lesão ortopédica e que sofreu ou pode ter sofrido uma lesão na cabeça, tal como uma lesão cerebral traumática (lct) leve, usando a proteína ácida fibrilar glial (gfap) e/ou a hidrolase carbóxi-terminal da ubiquitina l1 (uch-l1)
JP7379165B2 (ja) 2017-12-09 2023-11-14 アボット・ラボラトリーズ Ｇｆａｐとｕｃｈ－ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
EP3728321A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Use of pilra binding agents for treatment of a disease
CA3084064A1 (en) 2017-12-29 2019-07-04 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
US11512127B2 (en) 2018-02-14 2022-11-29 Viela Bio, Inc. Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
KR20200130696A (ko) 2018-03-12 2020-11-19 조에티스 서비시즈 엘엘씨 항-ngf 항체 및 이의 방법
CA3092078A1 (en) 2018-03-14 2019-09-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
CN111867377B (zh) 2018-03-14 2023-05-23 先锋国际良种公司 来自植物的杀昆虫蛋白及其使用方法
EP3788377A1 (en) 2018-05-04 2021-03-10 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
US11708571B2 (en) 2018-05-17 2023-07-25 Bp Corporation North America Inc. Production of 2-keto-3-deoxy-d-gluconic acid in filamentous fungi
US11337409B2 (en) 2018-06-08 2022-05-24 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain I
KR20210021002A (ko) 2018-06-13 2021-02-24 크리스탈 바이오사이언스 주식회사 다중 이황화 브릿지에 의해 안정화되고 유전자 변환에 의해 다양화되는 긴 cdr-h3s로 항체를 만드는 트랜스제닉 닭
WO2019244107A1 (en) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3824295A4 (en) 2018-07-18 2022-04-27 Janssen Biotech, Inc. PREDICTORS OF PROLONGED RESPONSE AFTER TREATMENT WITH AN ANTI-IL23 SPECIFIC ANTIBODY
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
US20220025391A1 (en) 2018-09-07 2022-01-27 Basf Plant Science Company Gmbh Improved method for the production of high levels of pufa in plants
WO2020049155A1 (en) 2018-09-07 2020-03-12 Basf Plant Science Company Gmbh Improved method for the production of high levels of pufa in plants
CA3110664A1 (en) 2018-09-07 2020-03-12 Basf Plant Science Company Gmbh Improved method for the production of high levels of pufa in plants
CA3113837C (en) 2018-09-24 2022-07-12 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
CA3114925A1 (en) 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途
EP3883961A1 (en) 2018-11-20 2021-09-29 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
MX2021005905A (es) 2018-11-20 2021-06-23 Janssen Biotech Inc Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
WO2020132557A1 (en) 2018-12-21 2020-06-25 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
WO2020148651A1 (en) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
CA3127748A1 (en) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
US20220177581A1 (en) 2019-03-11 2022-06-09 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
KR20210141976A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 제조 방법
US20200291107A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
CA3133388A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
JP2022525179A (ja) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための産生方法
MX2021011328A (es) 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
EP3966244A1 (en) 2019-05-09 2022-03-16 F. Hoffmann-La Roche AG Methods of making antibodies
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
US20220323580A1 (en) 2019-06-03 2022-10-13 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
EP3976183A1 (en) 2019-06-03 2022-04-06 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
US12209118B2 (en) 2019-07-08 2025-01-28 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021127547A2 (en) 2019-12-19 2021-06-24 Quidel Corporation Monoclonal antibody fusions
JP2023508871A (ja) 2019-12-20 2023-03-06 ビーエーエスエフ ソシエタス・ヨーロピア テルペンの毒性の低減および微生物中での生成可能性の増大
IL295387A (en) 2020-02-05 2022-10-01 Larimar Therapeutics Inc Tat peptide binding proteins and uses thereof
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
WO2021211331A1 (en) 2020-04-13 2021-10-21 Abbott Point Of Care Inc. METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
US20210338833A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
CN115516102A (zh) 2020-06-04 2022-12-23 艾瑟拜奥尼克斯公司 合成的檀香烯合酶
WO2022015619A2 (en) 2020-07-14 2022-01-20 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA3190230A1 (en) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
US20220043000A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Methods and kits for detecting sars-cov-2 protein in a sample
JP2023536737A (ja) 2020-08-04 2023-08-29 アボット・ラピッド・ダイアグノスティクス・インターナショナル・アンリミテッド・カンパニー Ｓａｒｓ－ｃｏｖ－２を検出するためのアッセイ
JP2023540611A (ja) 2020-09-11 2023-09-25 メドイミューン・リミテッド 治療用ｂ７－ｈ４結合分子
IL301264A (en) 2020-09-12 2023-05-01 Medimmune Ltd A scoring method for an anti-b7h4 antibody-drug conjugate therapy
WO2022076634A1 (en) 2020-10-08 2022-04-14 The Trustees Of Dartmouth College Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
US20220170948A1 (en) 2020-12-01 2022-06-02 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
EP4015626A1 (en) 2020-12-18 2022-06-22 Isobionics B.V. Enzymes and methods for fermentative production of monoterpene esters
EP4271998A1 (en) 2020-12-30 2023-11-08 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
EP4277665A1 (en) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
JP2024503657A (ja) 2021-01-13 2024-01-26 メモリアル スローン－ケタリング キャンサー センター 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
BR112023018400A2 (pt) 2021-03-12 2023-12-12 Janssen Biotech Inc Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23
JP2024510744A (ja) 2021-03-12 2024-03-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
CA3208011A1 (en) 2021-03-17 2022-09-22 Sarah Harris Methods of treating atopic dermatitis with anti il-13 antibodies
KR20250069981A (ko) 2021-03-18 2025-05-20 메디뮨 리미티드 Ccr9에 결합하는 치료용 결합 분자
EP4337689A1 (en) 2021-05-12 2024-03-20 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
EP4341699A1 (en) 2021-05-18 2024-03-27 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
WO2022243937A1 (en) 2021-05-20 2022-11-24 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
US20240118279A1 (en) 2021-06-14 2024-04-11 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
US20230042465A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
US20230038355A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
AU2022306144A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
CN117795087A (zh) 2021-08-02 2024-03-29 巴斯夫欧洲公司 用紫罗兰亚基乙烷合酶进行的芳香化合物的新颖生产
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
WO2023028186A1 (en) 2021-08-27 2023-03-02 Abbott Laboratories Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
AU2022339759A1 (en) 2021-08-31 2024-03-07 Abbott Laboratories Methods and systems of diagnosing brain injury
CA3232176A1 (en) 2021-09-30 2023-04-06 Beth MCQUISTON Methods and systems of diagnosing brain injury
EP4423126A1 (en) 2021-10-29 2024-09-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CA3238377A1 (en) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
IL313021A (en) 2021-11-23 2024-07-01 Janssen Biotech Inc A method for treating ulcerative colitis with a specific anti-IL23 antibody
EP4448179A1 (en) 2021-12-17 2024-10-23 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
EP4473311A1 (en) 2022-02-04 2024-12-11 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
AU2023298134A1 (en) 2022-06-29 2024-11-28 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
AU2023342055A1 (en) 2022-09-15 2025-03-13 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024059692A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
KR20250111179A (ko) 2022-11-22 2025-07-22 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
WO2024211475A1 (en) 2023-04-04 2024-10-10 Abbott Laboratories Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
WO2024226969A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
TW202508626A (zh) 2023-05-03 2025-03-01 美商健生生物科技公司 以針對ＩＬ－２３及ＴＮＦα的抗體的組合來治療克隆氏症之方法
WO2024228134A1 (en) 2023-05-03 2024-11-07 Janssen Biotech, Inc. Method of treating ulcerative colitis with a combination of antibodies to il-23 and tnf alpha
TW202448509A (zh) 2023-05-12 2024-12-16 美商建南德克公司 減少抗體黏度之方法及組成物
WO2025027472A2 (en) 2023-07-31 2025-02-06 Astrazeneca Ab Cd123 antibody-drug conjugates and methods of using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4321365A (en) * 1977-10-19 1982-03-23 Research Corporation Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4293652A (en) * 1979-05-25 1981-10-06 Cetus Corporation Method for synthesizing DNA sequentially
US4271145A (en) * 1979-10-22 1981-06-02 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4879219A (en) * 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4362867A (en) * 1980-12-10 1982-12-07 Research Corporation Recombinant cDNA construction method and hybrid nucleotides useful in cloning
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4490358A (en) * 1982-03-01 1984-12-25 President And Fellows Of Harvard College Screening vaccines and immunization process
USRE32833E (en) * 1982-03-01 1989-01-17 President And Fellows Of Harvard College Screening vaccines and immunization process
US4366264A (en) 1982-04-16 1982-12-28 Stanley Wawzonek Use of calcium metasilicate (wollastonite) as a formaldehyde suppressant for urea formaldehyde resins
DE3300632A1 (de) * 1982-12-13 1984-07-12 Christian Dipl.-Ing. 8900 Augsburg Strobel Verfahren genetischer analyse und synthese
DE3303173A1 (de) * 1982-12-13 1984-08-02 Christian Dipl.-Ing. 8900 Augsburg Strobel Verfahren genetischer analyse und synthese
DE3246071A1 (de) * 1982-12-13 1984-06-14 Christian Dipl.-Ing. 8900 Augsburg Strobel Verfahren genetischer analyse und synthese
US4634678A (en) * 1982-12-13 1987-01-06 Molecular Genetics Research And Development Limited Partnership Plasmid cloning and expression vectors for use in microorganisms
US4719179A (en) * 1984-11-30 1988-01-12 Pharmacia P-L Biochemicals, Inc. Six base oligonucleotide linkers and methods for their use
US4959312A (en) * 1985-05-31 1990-09-25 The University Of Tennessee Research Corporation Full spectrum mutagenesis
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NICHTS ERMITTELT *

Also Published As

Publication number Publication date
EP0229046A1 (fr) 1987-07-22
US5824514A (en) 1998-10-20
WO1986005803A1 (fr) 1986-10-09
DE3588239T3 (de) 2007-03-08
SG7992G (en) 1992-03-20
JP2584613B2 (ja) 1997-02-26
EP0590689B2 (fr) 2006-08-16
DE3588239T2 (de) 2003-01-02
DE3587814D1 (de) 1994-06-09
US5814476A (en) 1998-09-29
DE3588239D1 (de) 2002-06-27
CN86102090A (zh) 1986-11-05
GB8628313D0 (en) 1986-12-31
GB2183661B (en) 1989-06-28
JP2004089197A (ja) 2004-03-25
CA1341595C (en) 2009-04-28
DE3590766T (en, 2012) 1987-04-23
JPH0856667A (ja) 1996-03-05
DE3587814T2 (de) 1994-11-10
EP0229046B1 (fr) 1994-05-04
EP1186660A2 (fr) 2002-03-13
DE3590766C2 (en, 2012) 1991-01-10
IN165561B (en, 2012) 1989-11-18
HK20292A (en) 1992-03-27
EP1186660A3 (fr) 2002-03-20
US6569641B1 (en) 2003-05-27
JP2002325594A (ja) 2002-11-12
DE229046T1 (de) 1987-12-17
US5976862A (en) 1999-11-02
EP0590689A3 (en, 2012) 1994-04-20
US20040161816A1 (en) 2004-08-19
EP0590689B1 (fr) 2002-05-22
DE3546807C2 (en, 2012) 1991-03-28
AU4434585A (en) 1986-10-23
GB2183661A (en) 1987-06-10
JPS62502235A (ja) 1987-09-03
FR2579618A1 (fr) 1986-10-03
EP0590689A2 (fr) 1994-04-06
FR2579618B1 (fr) 1987-12-24
CH0229046H1 (de) 1998-07-15
US5817483A (en) 1998-10-06
CA1339937C (en) 1998-06-30
IN169027B (en, 2012) 1991-08-17
US5723323A (en) 1998-03-03

Similar Documents

Publication Publication Date Title
DE3546806C2 (en, 2012)
DE69128362T2 (de) Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
DE3051086C2 (en, 2012)
DE3588199T2 (de) Lymphokin-Herstellung und -Reinigung
DD159782A5 (de) Verfahren zur herstellung eines eine immunologische oder biologische aktivitaet von humanleukozyten-interferon aufweisendes polypeptids
DD210304A5 (de) Verfahren zur herstellung eines replikablen vektors
DD203331A5 (de) Verfahren zur erzeugung eines polypeptids
DD216044A5 (de) Verfahren zur herstellung eines rekombinierenden dna-klonierungsvektors
DE60127561T2 (de) Phagen-abhängige superproduktion biologisch aktiver proteine und peptide
DE69013811T2 (de) Verfahren zur Herstellung von antiviralem Protein unter Benützung von E.coli-Transformant, das Gen, das für dieses Protein kodiert und E.coli-Vektor benützt in diesem Verfahren.
DE60021188T2 (de) Modifizierter humaner granulozyten-kolonie stimulierenderfaktor sowie verfahren zur herstellung desselben
CH640268A5 (en) Process for the preparation of filamentous hybrid phages, novel hybrid phages and their use
DE69034051T2 (de) Stabil transformierte Hefezellen und ihre Verwendung zur Herstellung von Albumin
DE69318495T2 (de) Verfahren zur Reinigung des Big-Endothelin Proteins
EP1362125B8 (de) Verfahren zur identifizierung biologisch aktiver strukturen mikrobieller erreger
WO1997028263A1 (de) Rekombinante expression von s-layer-proteinen
DE3688816T2 (de) Dns-sequenz.
DE3751757T2 (de) Autonom replizierende DNA Fragmente aus Säugerzellen mit Affinität zu DNA bindenden Proteinen
EP2625275A1 (de) Verfahren zur semi-synthetischen herstellung hochreiner "minicircle" dna-vektoren aus plasmiden
DE69434072T2 (de) Regulierende nukleinsaeuresequenzen und verwendungen
EP0603672B1 (de) Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung
DE3689993T2 (de) Vektor für Expression und Sekretion von Produkten von heterologen Genen in Bacillus Subtilis.
DE69333106T2 (de) Polypeptidproduktion
DE3908897C2 (en, 2012)
CH685299A5 (de) Menschliches Fibroblasteninterferon beta 2, Verfahren zur Herstellung von menschlichem Fibroblasteninterferon beta 1 und beta 2 und deren Verwendung.

Legal Events

Date Code Title Description
8172 Supplementary division/partition in:

Ref country code: DE

Ref document number: 3590766

Format of ref document f/p: P

Q171 Divided out to:

Ref country code: DE

Ref document number: 3590766

8110 Request for examination paragraph 44
AH Division in

Ref country code: DE

Ref document number: 3590766

Format of ref document f/p: P

AH Division in

Ref country code: DE

Ref document number: 3590766

Format of ref document f/p: P

D2 Grant after examination
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: KAUFFMANN, STUART ALAN, SANTA FE, N.MEX., US

8381 Inventor (new situation)

Free format text: BALLIVET, MARC, GENF/GENEVE, CH KAUFFMAN, STUART ALAN, BRYN MAWR, PA., US